This study also represents the instance of a mutant KRAS oncogene hijacking the ALKBH5 PTMs/m6A methylation–mediated DNA damage response pathway to confer resistance to cytotoxic drugs in lung cancer cells. Here, KRAS is linked to lung carcinoma.